Transaction · 0001228684-26-000010

Link William J Phd

LINK WILLIAM J PHD, DIR, reported an open-market or private sale at Tarsus Pharmaceuticals, Inc. involving 66.000000 shares for an estimated $5280.66. Reported holdings after the transaction were 94487.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SDIR
TARSTarsus Pharmaceuticals, Inc.
Trade date
Sep 15, 2026
Filing date
Sep 17, 2026
View on SEC Insider profile
Disclosed value-$5.28kShares × reported price
Shares traded66$80.01 per share
Holdings after94.4kDirect
% of reported position traded0.07%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 94,553 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

TARS price since this filing

Daily closing prices, with the filing date and available return windows
TARS · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -12.4%1w ago -8.9%1d ago +1.2%
Returns since7d -3.9%30d -13.9%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001228684-26-000010
Common Stock
Transaction date
Sep 15, 2026
Filed Sep 17, 2026, 08:22 PM · 2d delay
Shares
66 sh
$80.01 per share
Estimated value
-$5.28k
Computed from shares × price
Holdings after
94,487 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

  2. F2

    The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

  3. F3

    The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide…

  4. F4

    The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide…

  5. F5

    Each RSU represents a contingent right to receive one share of the Company's common stock.

  6. F6

    RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/…

Original filing · 0001228684-26-000010
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

TARS